Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A study implicates the Hes1–Piezo1 signalling pathway in osteocytes in the pathogenesis of glucocorticoid-induced osteoporosis and demonstrates the beneficial effects of Yoda1, a Piezo1 agonist.
This Review discusses obstacles to health care equity in rheumatic disease, including access to health care and the use of inaccurate language when labelling population groups. The authors also highlight the siloing of biological and epidemiological research in rheumatology. They conclude with recommendations for achieving equitable precision medicine.
In 2024, studies using more advanced methods to calculate the minimal important change have described how different methods and timings of estimating minimal important changes can affect the estimates.
Results of the STEP 9 trial show that semaglutide leads to improvements in knee osteoarthritis-related symptoms. The findings support weight-management pharmacotherapies as a feasible option for management of knee osteoarthritis, but cost-effectiveness, risk of toxicity and likelihood of rebound must be considered.
In a phase III clinical trial of abatacept for idiopathic inflammatory myopathy, the primary endpoint was not met but the results suggest abatacept could have benefits in some subtypes of the disease.
Synovial dendritic cell profiles and localization patterns provide insights about the roles of dendritic cell subsets in the initiation, remission and relapse of rheumatoid arthritis.
In a new study, inhibition of CDK7 disrupted the RNA polymerase II transcription cycle, leading to anti-inflammatory effects and metabolic reprogramming in macrophages and attenuation of arthritis in mouse models.
Emerging research in intervertebral disc degeneration in 2024 highlights microbial, immune and inflammatory mechanisms that drive chronic low back pain. These insights pave the way for potential transformative therapies that address the root causes of intervertebral disc degeneration and could improve patient outcomes.
The updated 2023 EULAR recommendations for treatment of systemic sclerosis bring notable changes to recommendations for skin, peripheral vascular disease, interstitial lung disease and pulmonary arterial hypertension therapies, based on newer evidence. These updates provide the first glimmer of personalized patient management.
Here, we highlight three publications in 2024 that have advanced the field of molecular and immunological profiling, for the diagnosis, prognosis and treatment of patients with systemic autoimmune rheumatic diseases.
In this Review the author summarizes the current approaches for antigen-specific therapies in the treatment of autoimmune disease and highlights the challenges that need to be addressed for successful use of this therapeutic strategy.
The role of proteases in cartilage degradation and the development of osteoarthritis is undeniable. Despite over two decades of research on protease inhibitors, however, the transition from preclinical promise to clinical success remains elusive, underscoring the urgent need to critically appraise the challenges and limitations inherent in preclinical studies.
In this Review, Nigrovic and colleagues examine potential mechanisms underlying the paradoxical continuation of inflammation in arthritis, despite the increased numbers of regulatory T cells in inflamed joints, and discuss the implications for regulatory T cell-targeted therapeutic interventions in inflammatory arthritis.
A study reports that adipocytes can regulate the metabolism of fibroblasts in the healthy synovium via cortisol, but in inflammatory arthritis adiposity is lost and fibroblasts become pathogenic.
New research suggests that insulin-like growth factor 1 is an important contributor to Wnt-induced joint damage, and that its suppression could represent a promising therapeutic strategy for osteoarthritis.
The release of TGFβ by a subset of ITGA5+ synovial fibroblasts can promote the differentiation of pathogenic PD-1hiCXCL13+ T cells in RA, altering the inflammatory niche.
